摘要
目的探讨血液透析对宫颈癌晚期合并肾衰竭患者血清细胞因子及肿瘤标志物的影响。方法选择2017年1月至2019年12月丽水市中心医院血液净化中心收治的80例宫颈癌晚期合并肾衰竭患者作为研究对象。按照随机数字表法分成观察组(n=40)和对照组(n=40)。两组均接受化疗,观察组采用高通量血液透析治疗,对照组采用常规血液透析治疗。比较两组治疗后血清细胞因子白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-12(IL-12)和干扰素-γ(IFN-γ),以及血清肿瘤标志物癌胚抗原(CEA)、细胞角质素19(CYFRA21-1)、癌抗原125(CA125)、糖链抗原19-9(CA19-9)、鳞状上皮细胞癌抗原(SCC)水平。结果治疗后,观察组的IL-6、IL-8、IL-12、IFN-γ、CEA、CYFRA21-1、CA125、CA19-9、SCC水平低于对照组,差异具有统计学意义(P<0.05)。结论宫颈癌晚期合并肾衰竭患者采用血液透析的效果显著,且高通量血液透析在降低血清细胞因子和肿瘤标志物水平等方面优势更突出,同时可明显缓解症状,防止病情进一步恶化,值得推广。
Objective To investigate the effect of hemodialysis on serum cytokines and tumor markers in patients with advanced cervical cancer and renal failure. Methods 80 patients with advanced cervical cancer complicated with renal failure admitted to the Blood Purification Center of Lishui City Central Hospital from January 2017 to December 2019 were selected, and divided into observation group(n=40) and control group(n=40) as the research subjects according to random number table method. Both groups received chemotherapy, the observation group was treated with high-throughput hemodialysis, and the control group was treated with routine hemodialysis. The serum cytokines interleukin-6(IL-6), interleukin-8(IL-8), interleukin-12(IL-12) and interferon-γ(IFN-γ) were compared between the two groups after treatment. And serum levels of tumor markers CEA, CYFRA21-1, CA125, CA19-9, and SCC. Results After treatment, the levels of IL-6, IL-8, IL-12, IFN-γ, CEA, CYFRA21-1, CA125, CA19-9 and SCC in the observation group were lower than those in the control group(P<0.05). Conclusions The effect of hemodialysis in patients with advanced cervical cancer complicated with renal failure is significant, and the advantages of high-throughput hemodialysis in reducing serum cytokines and tumor markers are more prominent, and meanwhile it can significantly relieve symptoms and prevent further deterioration of the disease, which is worthy of promotion.
作者
张旭珍
李洁
周丽美
张彬娥
应金萍
ZHANG Xuzhen;LI Jie;ZHOU Limei;ZHANG Bin’e;YING Jinping(Blood Purification Center,Lishui City Central Hospital,Lishui 323000,Zhejiang,China;Blood Purification Center,the First Affiliated Hospital of Zhejiang University Medical College,Hangzhou 310000,Zhejiang,China)
出处
《中国性科学》
2021年第7期90-93,共4页
Chinese Journal of Human Sexuality